Characteristics of ITP patients
| ID . | Age, y . | Sex . | ITP duration,* y . | Plc,† ×109/L . | Treatment . | Analysis . |
|---|---|---|---|---|---|---|
| 1 | 32 | F | 3 | 58 | None | FC, ELISA |
| 2 | 33 | M | 0.5 | 47 | Prednisone 20 mg qd, IVIGs | FC, ELISA |
| 3 | 36 | F | 0.5 | 70 | None | FC, ELISA |
| 4 | 53 | M | 45 | 53 | None | FC, ELISA |
| 5 | 45 | M | 4 | 11 | None | FC, ELISA |
| 6 | 44 | M | 26 | 35 | None | FC, ELISA, MA |
| 7 | 59 | M | 31 | 11 | Prednisone 5 mg qd | MA |
| 8 | 53 | F | 2 | 45 | Prednisone 5 mg qd | MA, IHC |
| 9 | 28 | F | 5 | 50 | None | MA |
| 10 | 44 | F | 5 | 33 | Prednisone 10 mg qd | MA |
| 11 | 19 | F | 16 | 5 | None | IHC |
| 12 | 76 | F | 6 | 34 | None | IHC |
| 13 | 64 | F | 5 | 28 | None | IHC |
| 14 | 19 | F | 16 | 0 | None | IHC |
| 15 | 55 | F | 15 | 1 | None | IHC |
| 16 | 61 | M | 15 | 18 | None | IHC |
| 17 | 71 | F | 12 | 1 | None | IHC |
| 18 | 52 | M | 10 | 4 | None | IHC |
| 19 | 67 | M | 15 | 8 | None | IHC |
| 20 | 44 | F | 11 | 1 | None | IHC |
| 21 | 17 | F | 10 | 8 | None | IHC |
| 22 | 73 | F | 10 | 50 | None | IHC |
| 23 | 31 | F | 10 | 79 | None | IHC |
| 24 | 60 | M | 8 | 44 | None | IHC |
| 25 | 22 | F | 10 | 41 | None | IHC |
| 26 | 35 | F | 4 | 47 | None | IHC |
| ID . | Age, y . | Sex . | ITP duration,* y . | Plc,† ×109/L . | Treatment . | Analysis . |
|---|---|---|---|---|---|---|
| 1 | 32 | F | 3 | 58 | None | FC, ELISA |
| 2 | 33 | M | 0.5 | 47 | Prednisone 20 mg qd, IVIGs | FC, ELISA |
| 3 | 36 | F | 0.5 | 70 | None | FC, ELISA |
| 4 | 53 | M | 45 | 53 | None | FC, ELISA |
| 5 | 45 | M | 4 | 11 | None | FC, ELISA |
| 6 | 44 | M | 26 | 35 | None | FC, ELISA, MA |
| 7 | 59 | M | 31 | 11 | Prednisone 5 mg qd | MA |
| 8 | 53 | F | 2 | 45 | Prednisone 5 mg qd | MA, IHC |
| 9 | 28 | F | 5 | 50 | None | MA |
| 10 | 44 | F | 5 | 33 | Prednisone 10 mg qd | MA |
| 11 | 19 | F | 16 | 5 | None | IHC |
| 12 | 76 | F | 6 | 34 | None | IHC |
| 13 | 64 | F | 5 | 28 | None | IHC |
| 14 | 19 | F | 16 | 0 | None | IHC |
| 15 | 55 | F | 15 | 1 | None | IHC |
| 16 | 61 | M | 15 | 18 | None | IHC |
| 17 | 71 | F | 12 | 1 | None | IHC |
| 18 | 52 | M | 10 | 4 | None | IHC |
| 19 | 67 | M | 15 | 8 | None | IHC |
| 20 | 44 | F | 11 | 1 | None | IHC |
| 21 | 17 | F | 10 | 8 | None | IHC |
| 22 | 73 | F | 10 | 50 | None | IHC |
| 23 | 31 | F | 10 | 79 | None | IHC |
| 24 | 60 | M | 8 | 44 | None | IHC |
| 25 | 22 | F | 10 | 41 | None | IHC |
| 26 | 35 | F | 4 | 47 | None | IHC |
Plc indicates platelet count; FC, flow cytometry; ELISA, enzyme-linked immunosorbent assay of human fractalkine; qd, every day; IVIGs, intravenous immunoglobulins; MA, microarray analysis; and IHC, immunohistochemistry of stored bone marrow biopsy collected at initial diagnosis.
Patients 1 through 10: disease duration at time of enrollment in the indicated studies; patients 11 to 26: disease duration at time of retrospective analysis of bone marrow biopsy obtained at disease presentation.
Patients 1 through 10: platelet count at enrollment in the indicated studies; patients 11 to 26: platelet count at disease presentation and bone marrow biopsy, prior to therapy.